000			03287nam a2200325 4500
001			ESSALUD
005			20260817162604.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aMina, Roberto _eAutor _953814
245			_aTalquetamab–daratumumab in relapsed or refractory myeloma
300			_apáginas: 671-683
520			_aBackground: Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a limited effect on normal B cells. Methods: In a phase 3 trial, we randomly assigned patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy to receive talquetamab plus daratumumab and pomalidomide (Tal-DP), talquetamab plus daratumumab (Tal-D), or daratumumab plus pomalidomide and dexamethasone (DPd). The primary end point was progression-free survival as assessed by an independent review committee. Key secondary end points were overall response, complete response or better (complete or stringent complete response), measurable residual disease–negative complete response, and overall survival. Results: A total of 287, 287, and 290 patients were assigned to the Tal-DP, Tal-D, and DPd groups, respectively. At the interim analysis (median follow-up, 24.6 months), progression-free survival was significantly longer with Tal-DP and Tal-D than with DPd (24-month estimate, 81.3% and 77.6% vs. 51.2%; hazard ratio for disease progression or death, Tal-DP vs. DPd, 0.28 [95% confidence interval {CI}, 0.20 to 0.40], and Tal-D vs. DPd, 0.33 [95% CI, 0.24 to 0.46]; P<0.001 for both comparisons). The overall response was higher with Tal-DP and Tal-D than with DPd (88.2% and 88.5% vs. 77.6%), as was complete response or better (71.1% and 69.0% vs. 34.5%) and measurable residual disease–negative complete response (52.3% and 46.3% vs. 15.9%) (P<0.001 for all comparisons). Overall survival at 24 months was 89.2% with Tal-DP, 87.9% with Tal-D, and 79.1% with DPd (hazard ratio for death, Tal-DP vs. DPd, 0.47 [95% CI, 0.30 to 0.73], and Tal-D vs. DPd, 0.51 [95% CI, 0.33 to 0.78]). Serious adverse events occurred in 63.0%, 52.6%, and 53.7% of the patients in the Tal-DP, Tal-D, and DPd groups, respectively; fatal adverse events occurred in 1.8%, 4.0%, and 4.6%. Conclusions: Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, both Tal-DP and Tal-D led to significantly longer progression-free survival than DPd.
650			_aLEUCEMIA _933873
650			_aLINFOMA _939360
650			_aCUIDADOS INTENSIVOS GENERAL _954115
650			_aTRATAMIENTOS EN ONCOLOGÍA _953734
700			_aBeksac, Meral _954122
700			_aRodríguez-Otero, Paula _954123
700			_aChen,Wenming _953818
700			_aMateos, María-Victoria _954124
700			_aLi, Jian _954125
700			_aMoreau, Philippe _954126
700			_aCohen, Yael C. _954127
700			_aMin, Chang-Ki _954128
773	0		_022717 _922647 _dMassachusetts NEJM Group _oNEJM010 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-17 _zSQB
999			_c22827 _d22827